



STRATHEBY-LEWIS

PRESCRIPTION PRODUCTS

755 JEFFERSON ROAD, ROCHESTER, N. Y. 14603, P.O. BOX 1763, ROCHESTER, N. Y. 14603

(716) 231-1000

June 2, 1971

TO ALL FIELD SALES PERSONNEL

On May 26, 1971 the Director of the Bureau of Narcotics and Dangerous Drugs announced in the Federal Register the proposal of the agency to reclassify amphetamine and methamphetamine from Schedule III to Schedule II. The Director is acting under the provisions of the Comprehensive Drug Abuse Prevention and Control Act of 1970. Interested parties have thirty days to submit written comments and/or objections. June 30, 1971 has been set as the date for a hearing if comments and/or objections are deemed reasonable by the Director, and the final decision will be published after such hearings, if indeed, a hearing is granted.

We feel the reclassification of amphetamine and methamphetamine is inevitable. There is simply too great a political pressure. However, your management will review the entire actions of the Bureau of Narcotics and Dangerous Drugs with the best legal consultants available and determine our course of action. You will be kept advised of such developments.

More important is what the moving of Biphettamine® and Biphettamine-TO from Schedule III to Schedule II means to us.

1. From NOW until such time as the final decision is published, there is absolutely NO change in the status of Biphettamine® and Biphettamine-TO. We WILL continue our present program as is.... Kalyum, Biphettamine®, Biphettamine-TO, and Direthacal® for the remainder of Cycle #4.